MicroRNAs as molecular biological markers of benign hyperplasia and prostate cancer differentiation

Abstract

Diagnosis and treatment of prostate cancer (PCа) are associated with the serum level of prostate specific antigen (PSA). However, certain prostate diseases such as benign prostatic hyperplasia (BPH) and prostatitis can also affect PSA levels. The low specificity and sensitivity of PSA leads to a "unnecessary" prostate biopsy, which certainly makes this diagnostic method a controversial screening test. As a result, the discovery of new non-invasive molecular biological markers are necessary for the diagnosis, treatment, surveillance and prognosis of patients with diseases of prostate. This review aims to evaluate the "benefit" of miRNAs as molecular biological markers of BPH and PCa differentiation.

Keywords

• mirna
• benign prostatic hyperplasia
• prostate cancer
• lower urinary tract symptoms
• prostate specific antigen
• molecular biological markers
• ribonucleic acid
• review